Selected research
Industry Research
Acute Hyperammonemia Treatment Drugs Industry Research Report 2026
Market perspective
The global Acute Hyperammonemia Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Acute Hyperammonemia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Acute Hyperammonemia Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Acute Hyperammonemia Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Acute Hyperammonemia Treatment Drugs include Abbott Laboratories, Lee's Pharmaceutical, Amgen, Ultragenyx Pharmaceutical, Spyre Therapeutics, Sigmapharm Laboratories, Selecta Biosciences, Recordati and Orpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Acute Hyperammonemia Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acute Hyperammonemia Treatment Drugs Market by Company
Abbott Laboratories
Lee's Pharmaceutical
Amgen
Ultragenyx Pharmaceutical
Spyre Therapeutics
Sigmapharm Laboratories
Selecta Biosciences
Recordati
Orpharma
Medunik
Immedica
Arcturus Therapeutics
Acer Therapeutics
Acute Hyperammonemia Treatment Drugs Segment by Type
Sodium Phenylbutyrate
Sodium Benzoate
Arginine
Other
Acute Hyperammonemia Treatment Drugs Segment by Application
Hospital
Clinic
Acute Hyperammonemia Treatment Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Hyperammonemia Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Hyperammonemia Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Hyperammonemia Treatment Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Acute Hyperammonemia Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Acute Hyperammonemia Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Acute Hyperammonemia Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sodium Phenylbutyrate
- Sodium Benzoate
- Arginine
- Other
Applications
- Hospital
- Clinic
Companies covered
- Abbott Laboratories
- Lee's Pharmaceutical
- Amgen
- Ultragenyx Pharmaceutical
- Spyre Therapeutics
- Sigmapharm Laboratories
- Selecta Biosciences
- Recordati
- Orpharma
- Medunik
- Immedica
- Arcturus Therapeutics
- Acer Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Acute Hyperammonemia Treatment Drugs Market Size (2021-2032)
- 2.2.2 Global Acute Hyperammonemia Treatment Drugs Sales (2021-2032)
- 2.2.3 Global Acute Hyperammonemia Treatment Drugs Market Average Price (2021-2032)
- 2.3 Acute Hyperammonemia Treatment Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Sodium Phenylbutyrate
- 2.3.3 Sodium Benzoate
- 2.3.4 Arginine
- 2.3.5 Other
- 2.4 Acute Hyperammonemia Treatment Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Acute Hyperammonemia Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Acute Hyperammonemia Treatment Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Acute Hyperammonemia Treatment Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Acute Hyperammonemia Treatment Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Acute Hyperammonemia Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Acute Hyperammonemia Treatment Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Acute Hyperammonemia Treatment Drugs, Product Type & Application
- 3.8 Global Manufacturers of Acute Hyperammonemia Treatment Drugs, Established Date
- 3.9 Global Acute Hyperammonemia Treatment Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott Laboratories
- 4.1.1 Abbott Laboratories Company Information
- 4.1.2 Abbott Laboratories Business Overview
- 4.1.3 Abbott Laboratories Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Laboratories Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.1.5 Abbott Laboratories Recent Developments
- 4.2 Lee's Pharmaceutical
- 4.2.1 Lee's Pharmaceutical Company Information
- 4.2.2 Lee's Pharmaceutical Business Overview
- 4.2.3 Lee's Pharmaceutical Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lee's Pharmaceutical Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.2.5 Lee's Pharmaceutical Recent Developments
- 4.3 Amgen
- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.3.5 Amgen Recent Developments
- 4.4 Ultragenyx Pharmaceutical
- 4.4.1 Ultragenyx Pharmaceutical Company Information
- 4.4.2 Ultragenyx Pharmaceutical Business Overview
- 4.4.3 Ultragenyx Pharmaceutical Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ultragenyx Pharmaceutical Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.4.5 Ultragenyx Pharmaceutical Recent Developments
- 4.5 Spyre Therapeutics
- 4.5.1 Spyre Therapeutics Company Information
- 4.5.2 Spyre Therapeutics Business Overview
- 4.5.3 Spyre Therapeutics Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Spyre Therapeutics Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.5.5 Spyre Therapeutics Recent Developments
- 4.6 Sigmapharm Laboratories
- 4.6.1 Sigmapharm Laboratories Company Information
- 4.6.2 Sigmapharm Laboratories Business Overview
- 4.6.3 Sigmapharm Laboratories Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sigmapharm Laboratories Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.6.5 Sigmapharm Laboratories Recent Developments
- 4.7 Selecta Biosciences
- 4.7.1 Selecta Biosciences Company Information
- 4.7.2 Selecta Biosciences Business Overview
- 4.7.3 Selecta Biosciences Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Selecta Biosciences Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.7.5 Selecta Biosciences Recent Developments
- 4.8 Recordati
- 4.8.1 Recordati Company Information
- 4.8.2 Recordati Business Overview
- 4.8.3 Recordati Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Recordati Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.8.5 Recordati Recent Developments
- 4.9 Orpharma
- 4.9.1 Orpharma Company Information
- 4.9.2 Orpharma Business Overview
- 4.9.3 Orpharma Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orpharma Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.9.5 Orpharma Recent Developments
- 4.10 Medunik
- 4.10.1 Medunik Company Information
- 4.10.2 Medunik Business Overview
- 4.10.3 Medunik Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Medunik Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.10.5 Medunik Recent Developments
- 4.11 Immedica
- 4.11.1 Immedica Company Information
- 4.11.2 Immedica Business Overview
- 4.11.3 Immedica Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Immedica Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.11.5 Immedica Recent Developments
- 4.12 Arcturus Therapeutics
- 4.12.1 Arcturus Therapeutics Company Information
- 4.12.2 Arcturus Therapeutics Business Overview
- 4.12.3 Arcturus Therapeutics Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Arcturus Therapeutics Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.12.5 Arcturus Therapeutics Recent Developments
- 4.13 Acer Therapeutics
- 4.13.1 Acer Therapeutics Company Information
- 4.13.2 Acer Therapeutics Business Overview
- 4.13.3 Acer Therapeutics Acute Hyperammonemia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Acer Therapeutics Acute Hyperammonemia Treatment Drugs Product Portfolio
- 4.13.5 Acer Therapeutics Recent Developments
5 Global Acute Hyperammonemia Treatment Drugs Market Scenario by Region
- 5.1 Global Acute Hyperammonemia Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Acute Hyperammonemia Treatment Drugs Sales by Region: 2021-2032
- 5.2.1 Global Acute Hyperammonemia Treatment Drugs Sales by Region: 2021-2026
- 5.2.2 Global Acute Hyperammonemia Treatment Drugs Sales by Region: 2027-2032
- 5.3 Global Acute Hyperammonemia Treatment Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Acute Hyperammonemia Treatment Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Acute Hyperammonemia Treatment Drugs Revenue by Region: 2027-2032
- 5.4 North America Acute Hyperammonemia Treatment Drugs Market Facts & Figures by Country
- 5.4.1 North America Acute Hyperammonemia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Acute Hyperammonemia Treatment Drugs Sales by Country (2021-2032)
- 5.4.3 North America Acute Hyperammonemia Treatment Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Acute Hyperammonemia Treatment Drugs Market Facts & Figures by Country
- 5.5.1 Europe Acute Hyperammonemia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Acute Hyperammonemia Treatment Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Acute Hyperammonemia Treatment Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Acute Hyperammonemia Treatment Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Acute Hyperammonemia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Acute Hyperammonemia Treatment Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Acute Hyperammonemia Treatment Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Acute Hyperammonemia Treatment Drugs Market Facts & Figures by Country
- 5.7.1 South America Acute Hyperammonemia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Acute Hyperammonemia Treatment Drugs Sales by Country (2021-2032)
- 5.7.3 South America Acute Hyperammonemia Treatment Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Acute Hyperammonemia Treatment Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Acute Hyperammonemia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Acute Hyperammonemia Treatment Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Acute Hyperammonemia Treatment Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Acute Hyperammonemia Treatment Drugs Sales by Type (2021-2032)
- 6.1.1 Global Acute Hyperammonemia Treatment Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Acute Hyperammonemia Treatment Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Acute Hyperammonemia Treatment Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Acute Hyperammonemia Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Acute Hyperammonemia Treatment Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Acute Hyperammonemia Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Acute Hyperammonemia Treatment Drugs Sales by Application (2021-2032)
- 7.1.1 Global Acute Hyperammonemia Treatment Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Acute Hyperammonemia Treatment Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Acute Hyperammonemia Treatment Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Acute Hyperammonemia Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Acute Hyperammonemia Treatment Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Acute Hyperammonemia Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Acute Hyperammonemia Treatment Drugs Value Chain Analysis
- 8.1.1 Acute Hyperammonemia Treatment Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Acute Hyperammonemia Treatment Drugs Production Mode & Process
- 8.2 Acute Hyperammonemia Treatment Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Acute Hyperammonemia Treatment Drugs Distributors
- 8.2.3 Acute Hyperammonemia Treatment Drugs Customers
9 Global Acute Hyperammonemia Treatment Drugs Analyzing Market Dynamics
- 9.1 Acute Hyperammonemia Treatment Drugs Industry Trends
- 9.2 Acute Hyperammonemia Treatment Drugs Industry Drivers
- 9.3 Acute Hyperammonemia Treatment Drugs Industry Opportunities and Challenges
- 9.4 Acute Hyperammonemia Treatment Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst